News Category
In vitro ADME studies are critical for early assessment of drug candidates, helping to avoid costly clinical trial failures and accelerate development...
A new study reveals that individual microbiome composition influences susceptibility to sepsis, meningitis, and pneumonia from air pollution, highligh...
Peptide Wholesale Supply now applies HPLC testing and batch traceability to bulk orders of BPC-157, Semaglutide, and Tirzepatide, enhancing analytical...
A new push from experts and advocates urges small cell lung cancer patients to ask about clinical trials at their first appointment, as emerging thera...
GeoVax's agreement with CEPI to use its centralized laboratory network for the Phase 3 trial of GEO-MVA could provide independent validation of the va...
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNAs can restore full-length dystrophin and improve muscle...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities to help researchers engineer precise delivery pl...
BioCorRx Inc. appointed Richard J. Baum, former Acting Director of the White House Office of National Drug Control Policy, to its Strategic Advisory B...
Regentis Biomaterials has treated 43 of 80 patients in its Phase III GelrinC trial, secured a European manufacturing approval that boosts yield by 400...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective drug, has received FDA clearance for a Phase 2 trial that could revolutionize MS trea...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant that supports natural cartilage regeneration, offering a potential new ...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its BiTAC® T-cell engager platform...
Quantum BioPharma receives FDA clearance for its IND application for Lucid-MS, enabling a Phase 2 trial in multiple sclerosis and highlighting the pot...
Quantum BioPharma receives FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis candidate designed to protect and ...
Quantum BioPharma has received FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to protect and r...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting the company's late...
Onco-Innovations' CMO detailed the company's novel PNKP-targeting drug candidate ONC010, which uses synthetic lethality and nanoparticle delivery to p...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial for multiple sclerosis...
An expert flags that standard UTI diagnostic methods are flawed, leading to misdiagnosis and recurrent infections, emphasizing the urgent need for adv...
Silo Pharma's participation in the IPAC-RS forum underscores its progress in developing SPC-15, a nose-to-brain PTSD treatment, with stable preclinica...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial signifies a pivotal step toward a novel therapy that may repair myelin damage in multiple...
Quantum BioPharma’s Lucid-MS, a first-in-class myelin-protective multiple sclerosis drug candidate, has received FDA clearance to begin a Phase 2 tria...
GeoVax supports the new global mpox vaccine stockpile initiative as a step toward sustainable preparedness, highlighting its GEO-MVA candidate's readi...
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to strengthen its financial leadership and support the advancement of it...
Scinai Immunotherapeutics has strategically ended its PinCell collaboration to focus on its NanoAb platform and growing CDMO business, aiming to maxim...
Onco-Innovations advances its oncology pipeline with key manufacturing, IND-enabling, and capital developments, positioning ONC010 for clinical transl...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS marks a potential breakthrough in MS treatment by targeting myelin repair, a first f...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy (LITT) as a less invasive brain cancer treatm...
Ocumetics Technology Corp. has begun recruiting patients for Group Two of its human clinical study, moving beyond safety to evaluate the performance o...
Quantum BioPharma's FDA clearance to test Lucid-MS in phase 2 trials marks a historic step toward a therapy that could repair myelin, addressing an un...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the Pan African Clinical Trials Registry, marking a critical ...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS marks a significant milestone for a first-in-class multiple sclerosis treatment...
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials for multiple sclerosis marks a pivotal step in targeting demyelination direc...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a novel PAD2 inhibitor targeting demyelination, could herald a new approach to MS t...
Tonix Pharmaceuticals' promotion of Thomas Englese to Chief Commercial Officer underscores the company's strategic focus on expanding TONMYA's market ...
A large study reveals that the timing of brain metastasis development significantly impacts survival in colorectal cancer patients, underscoring the n...
Onco-Innovations has reported key preclinical progress for its PNKP inhibitor ONC010, including high-purity API manufacturing and plans for a First-in...
OS Therapies is set to present at the Moody Capital conference amid critical regulatory milestones for its lead candidate OST-HER2, potentially reshap...
A Swiss-led preclinical study reveals that administering immunotherapy before surgery significantly improves glioblastoma treatment outcomes, potentia...
The FDA's failure to aggressively enforce against online sellers of the unapproved investigational drug retatrutide has enabled a dangerous black mark...
New research from Mass General Brigham links unintended thymus radiation during lung cancer treatment to worse outcomes, suggesting that protecting th...
Tonix Pharmaceuticals' participation in the Cantor 2026 Global Healthcare Conference underscores its commercial-stage evolution and the strategic impo...
NurExone Biologic's upcoming presentation at a major life sciences conference highlights its exosome-based therapeutic platform and U.S. expansion str...
CNS Pharmaceuticals' Chief Business Officer details the company's strategic approach to in-licensing and acquisitions in oncology and neurology, highl...
Dr. Salman Fazal, a hematologist and stem cell transplant expert at UPMC Hillman Cancer Center, has been recognized as a Castle Connolly Top Doctor fo...
Quantum BioPharma receives a 'Buy' rating and $8.00 price target from Rodman & Renshaw, highlighting the potential of its lead candidate Lucid-MS for ...
NanoViricides is progressing its measles treatment NV-387 toward a Phase II trial as measles cases rise, leveraging strong preclinical data and FDA de...
TransCode Therapeutics' lead candidate TTX-MC138 demonstrated significant survival benefits in a preclinical breast cancer bone metastasis model, supp...
